These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25641224)

  • 1. Addressing viral hepatitis in the opiate substitution setting: an integrated nursing model of care.
    Fragomeli V; Weltman M
    J Gastroenterol Hepatol; 2015 Mar; 30 Suppl 2():6-11. PubMed ID: 25641224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
    Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
    Rance J; Newland J; Hopwood M; Treloar C
    Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
    Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
    Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Ohldieck C; Leiva RA; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    BMC Infect Dis; 2019 Nov; 19(1):943. PubMed ID: 31703669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
    Treloar C; Rance J; Dore GJ; Grebely J;
    J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV).
    Fadnes LT; Aas CF; Vold JH; Leiva RA; Ohldieck C; Chalabianloo F; Skurtveit S; Lygren OJ; Dalgård O; Vickerman P; Midgard H; Løberg EM; Johansson KA;
    PLoS Med; 2021 Jun; 18(6):e1003653. PubMed ID: 34061883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
    Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
    Treloar C; Rance J; Grebely J; Dore GJ
    Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
    Treloar C; Newland J; Rance J; Hopwood M
    J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy--factors associated with advanced fibrosis.
    Jerkeman A; Westin J; Lagging M; Norkrans G; Lidman C; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
    Scand J Infect Dis; 2014 May; 46(5):340-7. PubMed ID: 24552582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
    Gunn J; Higgs P
    Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
    Rockstroh JK; Bhagani S; Benhamou Y; Bruno R; Mauss S; Peters L; Puoti M; Soriano V; Tural C;
    HIV Med; 2008 Feb; 9(2):82-8. PubMed ID: 18257771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
    Treloar C; Hull P; Dore GJ; Grebely J
    Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
    Grady BP; Vanhommerig JW; Schinkel J; Weegink CJ; Bruisten SM; Lindenburg CE; Prins M
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1302-7. PubMed ID: 22825643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the management of hepatitis C virus infection among people who inject drugs.
    Robaeys G; Grebely J; Mauss S; Bruggmann P; Moussalli J; De Gottardi A; Swan T; Arain A; Kautz A; Stöver H; Wedemeyer H; Schaefer M; Taylor L; Backmund M; Dalgard O; Prins M; Dore GJ;
    Clin Infect Dis; 2013 Aug; 57 Suppl 2():S129-37. PubMed ID: 23884061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study.
    Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J;
    Int J Drug Policy; 2015 Nov; 26(11):1094-102. PubMed ID: 26145482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.